Evidence Hub

Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial

M. Marzinke, Brett Hanscom, Zhe Wang, S. Safren, C. Psaros, Deborah J. Donnell, Paul Richardson, P. Sullivan et al.

The Lancet HIV, 2023

13 citations

Abstract

Background: The HIV Prevention Trials Network (HPTN) 083 trial demonstrated that long-acting cabotegravir (CAB-LA) was more effective than tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in preventing HIV in cisgender men and transgender women (TGW) who have sex with men. In this report, we characterize the TGW cohort included in HPTN 083. Methods: An enrollment minimum of 10% TGW was set for HPTN 083. Socio-demographic characteristics, use of gender affirming hormone therapy (GAHT), and behavioral assessments were conducted throughout the trial. Laboratory testing and safety evaluations were performed. This is a secondary analysis of the HPTN 083 study (NCT02720094). Findings: HPTN 083 enrolled 570 TGW (304 TDF/FTC; 266 CAB-LA). TGW were primarily from Asia (225/570; 39.5%) and Latin America (205/570; 36.0%); 57.9% (330/570) reported GAHT use. Intimate partner violence was common, and 47.4% (270/570) and 30.2% (172/570) reported emotional or physical abuse, respectively; 56.7% (323/570) reported a history of childhood sexual abuse. Approximately one-quarter of TGW disagreed that they were at risk for HIV, and 24.9% (142/570) screened in for depressive symptoms. Incidence rates of syphilis, rectal gonorrhea, and chlamydia was 16.3%, 11.7%, and 20.6%, respectively. Frequency of adverse events was comparable between arms. Nine seroconversions occurred among TGW during the study blinded phase (7 TDF/FTC; 2 CAB-LA); overall incidence was 1.20 per 100 person-years (HR:…

How strong is the evidence?

Evidence Hub reads this as a secondary / pooled analysis, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free